Agios Pharmaceuticals, Inc.
NASDAQ: AGIO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Brian Goff
- Employees
- 486
- Headquarters
- Cambridge, United States
- IPO year
- 2013
- Market cap
- $2.2B
- Website
- https://www.agios.com
Loading AGIO…
Loading profile data…Frequently asked questions about AGIO
What does Agios Pharmaceuticals, Inc. (AGIO) do?
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, use...
Where does AGIO trade?
Agios Pharmaceuticals, Inc. (AGIO) trades on the NASDAQ Global Select.
What sector is AGIO in?
Agios Pharmaceuticals, Inc. (AGIO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Agios Pharmaceuticals, Inc.?
Brian Goff is the chief executive officer of Agios Pharmaceuticals, Inc. (AGIO).
Where is Agios Pharmaceuticals, Inc. headquartered?
Agios Pharmaceuticals, Inc. is headquartered in United States.
Does AGIO pay a dividend?
Agios Pharmaceuticals, Inc. (AGIO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AGIO go public?
Agios Pharmaceuticals, Inc. (AGIO) completed its initial public offering in 2013.